0001712762
true
0001712762
2023-03-24
2023-03-24
0001712762
BIAF:CommonStockParValue.007PerShareMember
2023-03-24
2023-03-24
0001712762
BIAF:TradeableWarrantsToPurchaseCommonStockMember
2023-03-24
2023-03-24
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
March
24, 2023
Date
of Report (Date of earliest event reported)
BIOAFFINITY
TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
001-41463 |
|
46-5211056 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
Number) |
22211
W Interstate 10
Suite
1206
San
Antonio, Texas 78257
(210)
698-5334
(Address
of principal executive offices and Registrant’s telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| |
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
|
| |
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
|
| |
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
|
| |
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c)) |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $.007 per share |
|
BIAF |
|
The
Nasdaq Stock Market LLC |
| Tradeable
Warrants to purchase Common Stock |
|
BIAFW |
|
The
Nasdaq Stock Market LLC |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
EXPLANATORY
NOTE
This
Current Report on Form 8-K/A (this “Amendment”) is being filed to amend the Current Report on Form 8-K filed by bioAffinity
Technologies, Inc. (the “Company”) on March 24, 2023 (the “Original Form 8-K”). The purpose of this Amendment
is to attach an updated press release as Exhibit 99.1, which corrects the URL for the Investor Relations section of the Company’s
website. No other changes are being made to the Original Form 8-K or to the original press release attached thereto.
Item
8.01. Other Events.
Recent
Press Release
On
March 24, 2023, the Company issued a press release announcing that it will report its fourth-quarter financial results for the quarter
ended December 31, 2022 after the market close on Friday, March 31, 2023. The Company also announced the details of a conference call
scheduled for Monday, April 3, 2023, to discuss its fourth-quarter results. The press release is filed as Exhibit 99.1 to this Form 8-K
and is incorporated herein by reference.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
BIOAFFINITY
TECHNOLOGIES, INC. |
| |
|
| |
By: |
/s/
Maria Zannes |
| |
|
Maria
Zannes |
| |
|
President
and Chief Executive Officer |
Dated:
March 24, 2023
Exhibit
99.1
 |
|
News
Release |
bioAffinity
Technologies to Report Fourth Quarter 2022
Financial
Results on March 31, 2023
Conference
Call scheduled on April 3, 2023, at 9 a.m. Eastern time
SAN
ANTONIO, Texas (March 24, 2023) – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced it will report
financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close. The Company will host
a conference call on Monday, April 3, 2023, at 9:00 a.m. Eastern time to discuss those results and answer questions.
| |
Event: |
bioAffinity
Technologies Fourth Quarter 2022 Financial Results |
| |
Date: |
Monday,
April 3, 2023 |
| |
Time: |
9:00
a.m. EDT |
| |
Toll
Free: |
1-877-270-2148 |
| |
International: |
1-412-902-6510 |
| |
Webcast: |
Webcast
link |
A
replay of the event will be available for 90 days at the webcast link above, which can also be found in the Investor Relations section
of bioAffinity’s website at https://ir.bioaffinitytech.com/.
About
bioAffinity Technologies, Inc.
bioAffinity
Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment.
The Company’s first product, CyPath® Lung, is a non-invasive test that has shown high sensitivity and specificity for
the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology
Services. OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to
kill cancer cells without harm to normal cells. Research and optimization of the Company’s platform technologies are conducted
in its laboratories at The University of Texas at San Antonio. For more information, visit www.bioaffinitytech.com.
Forward-Looking
Statements
This
press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Company’s
offering of common shares. Forward-looking statements can be identified by words such as “believes,” “expects,”
“estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or
the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on
any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters
discussed in this press release, except as may be required by applicable securities laws.
Contacts
bioAffinity
Technologies
Julie
Anne Overton
Director
of Communications
jao@bioaffinitytech.com
LHA
Investor Relations
Tirth
T. Patel
tpatel@lhai.com
#
# #